Nucleate works with startups that leverage life sciences to transform industries

Key figures

Key figures

Number of past
participating companies

Million USD
funds raised to date

Number of
locations nationwide

“Nucleate was an incredible opportunity to get hands-on experience learning the components of building a biotech as well as unparalleled access to mentors and resources. It’s an absolute must if you’re interested in biotech entrepreneurship.”
CAROLINE DAUGHERTY
HBS • SEORX
“I joined Nucleate to get exposure to early stage life company formation. The program connected me with my now Wayne, and offered us a risk-free way to validate our It gave us an opportunity to develop our story, practice it and receive invaluable feedback from the most investors in the space.”
HUNTER GOBLE
HBS • KARIVEZ
“Nucleate was an incredibly educational and eye-opening experience. Each session was led by biotech superstars and I learned so much from my team of MBAs/PhDs. I gained hands-on experience in many different aspects of the start-up process from pitching to VCs to building an operational budget. I would highly recommend the experience to anyone looking to jump into a career in biotech!”
JULIA PIAN
HBS • MANIFOLD BIO
“Nucleate Bio is rigorous and tough, but the materials the work produces are invaluable. Anyone serious about a startup should try hard to get into this program.”
JONATHAN RITTICHIER
WYSS INSTITUTE • ENPLUS ONE BIOSCIENCES
“The Nucleate program has been an incredible tool to refine our business model, building a solid network, and crafting a convincing pitch deck. I would recommend it to any scientist willing to explore the potential impact of her/his work in the biotech market.”
DANIELE FORESTI & EVERETT FROST
HMS & WYSS - HBS • ACOUSTICA BIO
“The Nucleate Program was instrumental in connecting our team to mentors who genuinely cared about our progress. Additionally, the regular events with industry experts and venture capitalists helped us ensure that we were framing our problem, solution, market, and milestones in a context that would be appealing to future funding sources. By the end of the program, we had constructed a strong pitch deck that led to several additional opportunities. On a personal note, I greatly enjoyed connecting with the other researchers and MBA students, many of whom I may never have met if not for the Nucleate Program.”
DANIELE FORESTI & EVERETT FROST
HMS & WYSS - HBS • ACOUSTICA BIO
“Nucleate was key to providing a scaffold for the team to get out of the lab and put together a viable business model. Some of the highlights of the program included mentorship from experienced biotech operators and company builders, feedback prioritizing application areas from the mapping experts at RA Capital, and finally putting it all together to pitch a mix of investors from both traditional biotech models and newer accelerators.”
GLEB KUZNETZOV & PIERCE OGDEN
HMS & WYSS • MANIFOLD BIO
“Nucleate helped launch our research idea into an exciting commercial opportunity! The value of Nucleate lies in its great leadership, extensive life sciences connections, and structured programming which was critical for the development of our business strategy and pitch to prospective investors.”
NATALIE FERGUSON & IVANA SHUI
HMS & HBS • SALVOS
“Nucleate is the reason Asan Therapeutics exists – this program is not just how we met but what enabled us to develop and chase dreams of entrepreneurship. We have had access to so many incredible mentors and opportunities that continue to help us shape our venture.”
ANANYA ZUTSHI & MORTEZA SARMADI
HBS & MIT • ASAN THERAPEUTICS

Company overview

Glyphic Bio Boston
Launched 2021
Platform
Protein sequencing platform for detection and identification of low-expression proteins, potentially including novel therapeutic targets.
AptaBridge Boston
Launched 2021
Therapeutics
Aptamer design platform enabling linkage of monospecific components to create multi-specifics or alter pharmacokinetics, targeting immunoncology.
Kano Therapeutics Boston
Launched 2021
Platform
DNA engineering platform leveraging M13 bacteriophage for scalable construction of gene-length ssDNA, targeting therapeutic production.
Concerto Biosciences Boston
Launched 2019
Therapeutics
Patented, data-driven platform for engineering microbial communities with useful properties.
NextRNA Boston
Launched 2019
Platform
NextRNA is transforming the non-coding RNA therapeutic space and is shifting the concept of undruggable into druggable.
Manifold Bio Boston
Launched 2019
Platform
A novel experimental platform that generates pharmacological measurements on millions of therapeutic protein variants in parallel.
Acoustica Bio Boston
Launched 2019
Platform
Improving clinical care of millions of patients by reformulating existing intravenously-delivered drugs in a subcutaneous form, using a patented acoustophoretic printing approach.
Beacon Biomimetics Boston
Launched 2020
Medical Devices
Developd PhonoGraft, a novel device composed of a synthetic, biodegradable elastomer that can restore biomimetic stiffness in the tympanic membrane to improve hearing outcomes.
PionEar Technologies Boston
Launched 2020
Medical Devices
Developing a new generation of fluid-guiding and biocontamination-resistant tympanostomy tubes that allow antibiotic drops to penetrate the middle ear more efficiently.
Limax Bio Boston
Launched 2021
Diagnostics
Tissue adhesive combining high strength, high adhesion energy, and biocompatibility for wound healing across multiple tissue types.
Ilesa Bio Boston
Launched 2021
Therapeutics
Biotherapeutic for shielding native gut microbiota from antibiotics, for prevention of dysbiosis-related inflammatory and metabolic disorders.
Crisscross Nano Boston
Launched 2021
Diagnostics
Diagnostic platform leveraging DNA nanostructures for rapid, low-cost detection of nucleic acids and proteins, initially targeting infectious disease.
Carmel Medicine Boston
Launched 2021
Therapeutics
Therapeutic neural growth factor (NGF) addressing the historically dose-limiting side effect of pain, initially targeting peripheral neuropathy.
PhageLink Boston
Launched 2021
Medical Devices
Genetically engineered, biocompatible hydrogel that is customizable for broad therapeutic applications in drug delivery and 3D printing in vivo.
Kumuda Boston
Launched 2021
Platform
In silico drug discovery platform analyzing protein interaction, structure, and drug target homology across the human genome to discover drug targets.
MicroLife Boston
Launched 2021
Eco
Creating a stable probiotic spray using a patented silk and trehalose technology to deliver an engineered microbe microenvironment.
Syntrophia Boston
Launched 2021
Eco
Creating assay kits to continuously monitor and supercharge biomanufacturing and fermentation processes using FISH-TAMB mRNA imaging technology.
PicoGreens Boston
Launched 2021
Eco
Developing a new type sustainable feedstock for biomanufacturing and cell culture processes, composed of fast-growing cyanobacteria.
Farm Forward Boston
Launched 2021
Eco
Generating plant tissue-like materials for a range of applications.
Eat PET Boston
Launched 2021
Eco
High performance enzymes and microbes to convert low-value plastics into high-value chemicals and products.
Asan Therapeutics Boston
Launched 2020
Therapeutics
Developing a drug delivery platform dedicated to making the delivery of biologics easier.
CellBLAST Boston
Launched 2020
Platform
Cutting-edge machine learning algorithms designed for multi-modal analysis of cell states and their underlying dynamic changes across conditions.
Enplus One Bio Boston
Launched 2020
Therapeutics
Novel enzymatic RNA oligonucleotide synthesis platform to produce custom RNA sequences comprised of natural and modified nucleobases; aim to address limitations of traditional chemical RNA synthesis methods.
Karivez Boston
Launched 2020
Therapeutics
Therapeutics company founded on technology that transports biologic drugs across epithelial barriers within the body, to enhance biodistribution and enable oral delivery of drugs that previously had to be injected or infused.
Platelet Xploration Boston
Launched 2020
Diagnostics
Aims to improve outcomes for patients with platelet-related disease; first project willl develop better tests to predict bleeding in immune thrombocytopenia.
RCD Boston
Launched 2020
Platform
Proprietary algorithm to discover gene targets for next generation chemotherapy using computational analysis.
Salvos Boston
Launched 2020
Therapeutics
T-cell therapy company developing cancer therapeutics by improving T-cell functions utilizing our novel immune cell engineering platform; enhancing T-cells to unlock the power of a patient's immune system to fight against cancer.
SUPER Boston
Launched 2020
Diagnostics
Microsampling immunoassay with superior sensitivity to full-scale solutions and a potentially lab independent workflow, based on programmable DNA synthesis technology.
Akili Boston
Launched 2019
Diagnostics
Cancer diagnostics using a novel machine learning approach.
Auxono Boston
Launched 2019
Therapeutics
Developing novel therapies against Hippo-YAP signaling pathway, with applications in liver cancer and uveal melanoma.
Glyphic Bio
AptaBridge
Kano Therapeutics
Concerto Biosciences
NextRNA
Manifold Bio
Acoustica Bio
Beacon Biomimetics
PionEar Technologies
Limax Bio
Ilesa Bio
Crisscross Nano
Carmel Medicine
PhageLink
Kumuda
MicroLife
Syntrophia
PicoGreens
Farm Forward
Eat PET
Asan Therapeutics
CellBLAST
Enplus One Bio
Karivez
Platelet Xploration
RCD
Salvos
SUPER
Akili
Auxono